Reevaluation of Treatment Outcomes Following Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer

Reevaluation of Treatment Outcomes Following Conversion Surgery After Introduction of New Chemotherapy for Unresectable Locally Advanced Pancreatic Cancer - Reevaluating Conversion Surgery for Locally Advanced Pancreatic Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057694

Enrollment

950

Registered

2025-04-24

Start date

2023-10-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable Locally Advanced Pancreatic Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cases diagnosed as invasive pancreatic ductal carcinoma on postoperative pathology (however, if the case achieved complete response [CR], it must have been diagnosed as adenocarcinoma on preoperative cytology or histology). 2. Cases diagnosed at initial diagnosis as unresectable locally advanced pancreatic cancer (based on the definition of locally advanced pancreatic cancer in the NCCN Guidelines 2022 Edition Version 2). pancreatic head cancer with >180 degree contact with the superior mesenteric artery (SMA) or celiac artery (CA); pancreatic body/tail cancer with >180 degree contact with the SMA or CA, or CA involvement with aortic invasion; and unreconstructable superior mesenteric vein/portal vein invasion or occlusion. 3. Patients who underwent FOLFIRINOX therapy, GnP therapy, or its variants (mFOLFIRINOX, SOXIRI, GAS, etc.) as first-line treatment between January 2015 and December 2020, followed by CS. The presence or absence of radiotherapy is not a criterion. 4. Patients with no macroscopic peritoneal dissemination but microscopic peritoneal dissemination (CY) are eligible. 5. The types of pancreatic resection included are pancreaticoduodenectomy, pancreatic tail resection (including DP-CAR), total pancreatectomy, and others.

Exclusion criteria

Exclusion criteria: Distant metastasis at initial diagnosis Invasive intraductal papillary mucinous carcinoma Active multiple primary cancers Cases deemed inappropriate by the multidisciplinary team.

Design outcomes

Primary

Measure	Time frame
Overall Survival from the start of initial treatment	—

Secondary

Measure	Time frame
Overall survival after CS, recurrence-free survival after CS, preoperative treatment period, postoperative short-term outcomes (complications, postoperative mortality), recurrence patterns, and factors contributing to survival.	—

Countries

Japan

Contacts

Public ContactSatoshi Yasuda

Nara Medical University Department of Sugery

hi22zd@naramed-u.ac.jp0744298863

Outcome results